Verve Therapeutics Q1 2024 Earnings Report

Verve Therapeutics EPS Results

• Actual EPS: -$0.59
• Consensus EPS: -$0.70
• Beat/Miss: Beat by +$0.11
• One Year Ago EPS: N/A

Verve Therapeutics Revenue Results

• Actual Revenue: $5.70 million
• Expected Revenue: $2.11 million
• Beat/Miss: Beat by +$3.59 million
• YoY Revenue Growth: +305.60%

Verve Therapeutics Announcement Details

• Quarter: Q1 2024
• Date: 5/8/2024
• Time: Before Market Opens

Verve Therapeutics (NASDAQ:VERV), a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.